Literature DB >> 15026564

Combined exchange transfusion and chelation therapy for neonatal lead poisoning.

Mark B Mycyk1, Jerrold B Leikin.   

Abstract

OBJECTIVE: To describe the results of combined exchange transfusion and chelation therapy in a neonate with an elevated blood lead level (BLL). CASE
SUMMARY: A 34-year-old Latina woman with a long history of pica (eating glazed pottery) gave birth to a healthy-appearing girl at 40 weeks of gestation. The mother's preconception BLL was 117 microg/dL and remained elevated throughout pregnancy. At parturition, the mother's BLL was 87 microg/dL and the infant's cord BLL was 100 microg/dL. The infant underwent single-volume exchange transfusion within 12 hours of birth. BLL was 28 microg/dL following the exchange, and a 5-day course of chelation with dimercaprol and CaNa2 ethylenediamine tetraacetic acid was initiated at 36 hours of life. The infant's BLL was 37 microg/dL at the end of inpatient chelation. DISCUSSION: Long-term neurologic disability from in utero lead exposure is well described, but the optimal treatment of elevated neonatal BLLs in healthy-appearing infants at the time of birth is not established. This strategy of combined chelation and exchange transfusion therapy was well tolerated and resulted in decreased lead levels, but the long-term neurologic efficacy of our combination strategy remains to be seen.
CONCLUSIONS: Combined exchange transfusion and chelation therapy resulted in rapidly decreased lead levels in a neonate with chronic in utero lead exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026564     DOI: 10.1345/aph.1D475

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Pica during pregnancy among Mexican-born women: a formative study.

Authors:  Janice W Lin; Luisa Temple; Celina Trujillo; Fabiola Mejia-Rodriquez; Lisa Goldman Rosas; Lia Fernald; Sera L Young
Journal:  Matern Child Nutr       Date:  2014-05-01       Impact factor: 3.092

2.  Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation.

Authors:  Scott C Miller; Xuli Wang; Beth M Bowman
Journal:  Health Phys       Date:  2010-09       Impact factor: 1.316

3.  The usefulness of chelation therapy for the remission of symptoms caused by previous treatment with mercury-containing pharmaceuticals: a case report.

Authors:  Serafina Corsello; Alessandro Fulgenzi; Daniele Vietti; Maria Elena Ferrero
Journal:  Cases J       Date:  2009-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.